Shares of VIA Pharmaceuticals Inc. jumped 45 percent Friday after the company presented a Phase II subset analysis showing that VIA-2291 reduced unstable coronary plaques in patients with acute coronary syndrome. (BioWorld Today) Read More
In a fight between rich corporate raiders and the management of modestly sized biotech companies, all my instincts are to side with the latter. (BioWorld Perspectives) Read More